Akebia Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKBA and other ETFs, options, and stocks.About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders.
CEOJohn P. Butler
CEOJohn P. Butler
Employees181
Employees181
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2007
Founded2007
Employees181
Employees181
AKBA Key Statistics
Market cap538.24M
Market cap538.24M
Price-Earnings ratio-11.77
Price-Earnings ratio-11.77
Dividend yield—
Dividend yield—
Average volume7.16M
Average volume7.16M
High today$2.12
High today$2.12
Low today$1.96
Low today$1.96
Open price$2.04
Open price$2.04
Volume4.48M
Volume4.48M
52 Week high$4.08
52 Week high$4.08
52 Week low$1.52
52 Week low$1.52
Stock Snapshot
With a market cap of 538.24M, Akebia Therapeutics(AKBA) trades at $2.06. The stock has a price-to-earnings ratio of -11.77.
On 2025-11-09, Akebia Therapeutics(AKBA) stock moved within a range of $1.96 to $2.12. With shares now at $2.06, the stock is trading +5.1% above its intraday low and -2.8% below the session's peak.
Trading volume for Akebia Therapeutics(AKBA) stock has reached 4.48M, versus its average volume of 7.16M.
Over the past 52 weeks, Akebia Therapeutics(AKBA) stock has traded between a high of $4.08 and a low of $1.52.
Over the past 52 weeks, Akebia Therapeutics(AKBA) stock has traded between a high of $4.08 and a low of $1.52.
People also own
Based on the portfolios of people who own AKBA. This list is generated using Robinhood data, and it’s not a recommendation.